New cancer drug combo tested in patients out of options
NCT ID NCT05174585
Summary
This early-stage study tested a new drug called JAB-BX102, both alone and combined with an existing immunotherapy (pembrolizumab), in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe dose levels and see if the treatment showed any early signs of shrinking tumors. It was a small, first look to gather initial safety and activity data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Huashan Hospital
Shanghai, Shanghai Municipality, 200040, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233004, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
Conditions
Explore the condition pages connected to this study.